Interpreting P Values in Pharmacogenetic Studies: A Call for Process and Perspective
- 10 October 2007
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (29), 4513-4515
- https://doi.org/10.1200/jco.2007.12.7803
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian CancerJournal of Clinical Oncology, 2007
- Genome-wide association study identifies novel breast cancer susceptibility lociNature, 2007
- Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride LevelsScience, 2007
- A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility VariantsScience, 2007
- A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerNature Genetics, 2007
- TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?Trends in Pharmacological Sciences, 2006
- The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]DihydrouracilClinical Cancer Research, 2006
- Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian CarcinomaJNCI Journal of the National Cancer Institute, 2004
- Assessing the function of genetic variants in candidate gene association studiesNature Reviews Genetics, 2004
- Medical and Societal Consequences of the Human Genome ProjectNew England Journal of Medicine, 1999